Head and neck cancer reirradiation with interstitial high‐dose‐rate brachytherapy
Background As high‐dose‐rate (HDR) brachytherapy can preferentially spare normal anatomic structures surrounding the radiation target, we report on our experience using this technique in head and neck cancer reirradiation. Methods Twenty patients received HDR brachytherapy reirradiation with curativ...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2018-07, Vol.40 (7), p.1524-1533 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1533 |
|---|---|
| container_issue | 7 |
| container_start_page | 1524 |
| container_title | Head & neck |
| container_volume | 40 |
| creator | Hegde, John V. Demanes, D. Jeffrey Veruttipong, Darlene Chin, Robert K. Park, Sang‐June Kamrava, Mitchell |
| description | Background
As high‐dose‐rate (HDR) brachytherapy can preferentially spare normal anatomic structures surrounding the radiation target, we report on our experience using this technique in head and neck cancer reirradiation.
Methods
Twenty patients received HDR brachytherapy reirradiation with curative or palliative intent from 2010‐2015. Clinical and toxicity outcomes were recorded. Actuarial outcomes were calculated using Kaplan‐Meier analysis.
Results
For curative treatment, actuarial 2‐year rates of local control and overall survival (OS) were 73% and 56%, respectively. Palliatively, a 6‐month local control rate of 65% was seen. Age >70 years was associated with poorer OS (P = .042). Prior salvage resection showed a trend toward improved local control and OS (P = .069 and P = .063, respectively). Thirty‐three percent had grade 3 to 4 late toxicities.
Conclusion
Curative‐intent HDR brachytherapy reirradiation can provide excellent local control and encouraging OS. Given the late toxicity rates, patient selection is essential, with particular utility for younger patients or those treated with salvage resection. |
| doi_str_mv | 10.1002/hed.25137 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2066195254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2066195254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2687-5403814321610c5fc5d3bf951b6bdb6faaf69b520b01565e6221c7331f177e1e3</originalsourceid><addsrcrecordid>eNp1kLFOwzAQQC0EoqUw8AMoEhNDWp8d282IoFCkSix0tmzHIS5tUmxXVTY-gW_kS0hpOzLd6fT0TnoIXQMeAsZkVNliSBhQcYL6gHORYpqJ092e0ZRikfXQRQgLjDHlGTlHPZIzQYFAH82nVhWJqouktuYjMao21ifeOu9V4VR0TZ1sXawSV0frQ3TRqWVSuffq5-u7aILthlfRJtorU7Wxsl6t20t0VqplsFeHOUDzp8nbwzSdvT6_PNzPUkP4WKQsw3QMGSXAARtWGlZQXeYMNNeF5qVSJc81I1hjYJxZTggYQSmUIIQFSwfodu9d--ZzY0OUi2bj6-6lJJhzyBlhWUfd7SnjmxC8LeXau5XyrQQsdwFlF1D-BezYm4Nxo1fd9Ugei3XAaA9s3dK2_5vkdPK4V_4Cd717Kw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2066195254</pqid></control><display><type>article</type><title>Head and neck cancer reirradiation with interstitial high‐dose‐rate brachytherapy</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hegde, John V. ; Demanes, D. Jeffrey ; Veruttipong, Darlene ; Chin, Robert K. ; Park, Sang‐June ; Kamrava, Mitchell</creator><creatorcontrib>Hegde, John V. ; Demanes, D. Jeffrey ; Veruttipong, Darlene ; Chin, Robert K. ; Park, Sang‐June ; Kamrava, Mitchell</creatorcontrib><description>Background
As high‐dose‐rate (HDR) brachytherapy can preferentially spare normal anatomic structures surrounding the radiation target, we report on our experience using this technique in head and neck cancer reirradiation.
Methods
Twenty patients received HDR brachytherapy reirradiation with curative or palliative intent from 2010‐2015. Clinical and toxicity outcomes were recorded. Actuarial outcomes were calculated using Kaplan‐Meier analysis.
Results
For curative treatment, actuarial 2‐year rates of local control and overall survival (OS) were 73% and 56%, respectively. Palliatively, a 6‐month local control rate of 65% was seen. Age >70 years was associated with poorer OS (P = .042). Prior salvage resection showed a trend toward improved local control and OS (P = .069 and P = .063, respectively). Thirty‐three percent had grade 3 to 4 late toxicities.
Conclusion
Curative‐intent HDR brachytherapy reirradiation can provide excellent local control and encouraging OS. Given the late toxicity rates, patient selection is essential, with particular utility for younger patients or those treated with salvage resection.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.25137</identifier><identifier>PMID: 29573121</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Brachytherapy ; Cancer ; Head & neck cancer ; head and neck cancer ; low‐dose‐rate and high‐dose‐rate (HDR) brachytherapy ; Patients ; Radiation therapy ; reirradiation ; salvage treatment ; Toxicity</subject><ispartof>Head & neck, 2018-07, Vol.40 (7), p.1524-1533</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2687-5403814321610c5fc5d3bf951b6bdb6faaf69b520b01565e6221c7331f177e1e3</citedby><cites>FETCH-LOGICAL-c2687-5403814321610c5fc5d3bf951b6bdb6faaf69b520b01565e6221c7331f177e1e3</cites><orcidid>0000-0001-8098-5767</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.25137$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.25137$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29573121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hegde, John V.</creatorcontrib><creatorcontrib>Demanes, D. Jeffrey</creatorcontrib><creatorcontrib>Veruttipong, Darlene</creatorcontrib><creatorcontrib>Chin, Robert K.</creatorcontrib><creatorcontrib>Park, Sang‐June</creatorcontrib><creatorcontrib>Kamrava, Mitchell</creatorcontrib><title>Head and neck cancer reirradiation with interstitial high‐dose‐rate brachytherapy</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
As high‐dose‐rate (HDR) brachytherapy can preferentially spare normal anatomic structures surrounding the radiation target, we report on our experience using this technique in head and neck cancer reirradiation.
Methods
Twenty patients received HDR brachytherapy reirradiation with curative or palliative intent from 2010‐2015. Clinical and toxicity outcomes were recorded. Actuarial outcomes were calculated using Kaplan‐Meier analysis.
Results
For curative treatment, actuarial 2‐year rates of local control and overall survival (OS) were 73% and 56%, respectively. Palliatively, a 6‐month local control rate of 65% was seen. Age >70 years was associated with poorer OS (P = .042). Prior salvage resection showed a trend toward improved local control and OS (P = .069 and P = .063, respectively). Thirty‐three percent had grade 3 to 4 late toxicities.
Conclusion
Curative‐intent HDR brachytherapy reirradiation can provide excellent local control and encouraging OS. Given the late toxicity rates, patient selection is essential, with particular utility for younger patients or those treated with salvage resection.</description><subject>Brachytherapy</subject><subject>Cancer</subject><subject>Head & neck cancer</subject><subject>head and neck cancer</subject><subject>low‐dose‐rate and high‐dose‐rate (HDR) brachytherapy</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>reirradiation</subject><subject>salvage treatment</subject><subject>Toxicity</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kLFOwzAQQC0EoqUw8AMoEhNDWp8d282IoFCkSix0tmzHIS5tUmxXVTY-gW_kS0hpOzLd6fT0TnoIXQMeAsZkVNliSBhQcYL6gHORYpqJ092e0ZRikfXQRQgLjDHlGTlHPZIzQYFAH82nVhWJqouktuYjMao21ifeOu9V4VR0TZ1sXawSV0frQ3TRqWVSuffq5-u7aILthlfRJtorU7Wxsl6t20t0VqplsFeHOUDzp8nbwzSdvT6_PNzPUkP4WKQsw3QMGSXAARtWGlZQXeYMNNeF5qVSJc81I1hjYJxZTggYQSmUIIQFSwfodu9d--ZzY0OUi2bj6-6lJJhzyBlhWUfd7SnjmxC8LeXau5XyrQQsdwFlF1D-BezYm4Nxo1fd9Ugei3XAaA9s3dK2_5vkdPK4V_4Cd717Kw</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Hegde, John V.</creator><creator>Demanes, D. Jeffrey</creator><creator>Veruttipong, Darlene</creator><creator>Chin, Robert K.</creator><creator>Park, Sang‐June</creator><creator>Kamrava, Mitchell</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-8098-5767</orcidid></search><sort><creationdate>201807</creationdate><title>Head and neck cancer reirradiation with interstitial high‐dose‐rate brachytherapy</title><author>Hegde, John V. ; Demanes, D. Jeffrey ; Veruttipong, Darlene ; Chin, Robert K. ; Park, Sang‐June ; Kamrava, Mitchell</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2687-5403814321610c5fc5d3bf951b6bdb6faaf69b520b01565e6221c7331f177e1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Brachytherapy</topic><topic>Cancer</topic><topic>Head & neck cancer</topic><topic>head and neck cancer</topic><topic>low‐dose‐rate and high‐dose‐rate (HDR) brachytherapy</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>reirradiation</topic><topic>salvage treatment</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hegde, John V.</creatorcontrib><creatorcontrib>Demanes, D. Jeffrey</creatorcontrib><creatorcontrib>Veruttipong, Darlene</creatorcontrib><creatorcontrib>Chin, Robert K.</creatorcontrib><creatorcontrib>Park, Sang‐June</creatorcontrib><creatorcontrib>Kamrava, Mitchell</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hegde, John V.</au><au>Demanes, D. Jeffrey</au><au>Veruttipong, Darlene</au><au>Chin, Robert K.</au><au>Park, Sang‐June</au><au>Kamrava, Mitchell</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Head and neck cancer reirradiation with interstitial high‐dose‐rate brachytherapy</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2018-07</date><risdate>2018</risdate><volume>40</volume><issue>7</issue><spage>1524</spage><epage>1533</epage><pages>1524-1533</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
As high‐dose‐rate (HDR) brachytherapy can preferentially spare normal anatomic structures surrounding the radiation target, we report on our experience using this technique in head and neck cancer reirradiation.
Methods
Twenty patients received HDR brachytherapy reirradiation with curative or palliative intent from 2010‐2015. Clinical and toxicity outcomes were recorded. Actuarial outcomes were calculated using Kaplan‐Meier analysis.
Results
For curative treatment, actuarial 2‐year rates of local control and overall survival (OS) were 73% and 56%, respectively. Palliatively, a 6‐month local control rate of 65% was seen. Age >70 years was associated with poorer OS (P = .042). Prior salvage resection showed a trend toward improved local control and OS (P = .069 and P = .063, respectively). Thirty‐three percent had grade 3 to 4 late toxicities.
Conclusion
Curative‐intent HDR brachytherapy reirradiation can provide excellent local control and encouraging OS. Given the late toxicity rates, patient selection is essential, with particular utility for younger patients or those treated with salvage resection.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29573121</pmid><doi>10.1002/hed.25137</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8098-5767</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2018-07, Vol.40 (7), p.1524-1533 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_journals_2066195254 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Brachytherapy Cancer Head & neck cancer head and neck cancer low‐dose‐rate and high‐dose‐rate (HDR) brachytherapy Patients Radiation therapy reirradiation salvage treatment Toxicity |
| title | Head and neck cancer reirradiation with interstitial high‐dose‐rate brachytherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A23%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Head%20and%20neck%20cancer%20reirradiation%20with%20interstitial%20high%E2%80%90dose%E2%80%90rate%20brachytherapy&rft.jtitle=Head%20&%20neck&rft.au=Hegde,%20John%20V.&rft.date=2018-07&rft.volume=40&rft.issue=7&rft.spage=1524&rft.epage=1533&rft.pages=1524-1533&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.25137&rft_dat=%3Cproquest_cross%3E2066195254%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2066195254&rft_id=info:pmid/29573121&rfr_iscdi=true |